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Alternative Conformations of HIV-1 V3 Loops
Mimic  Hairpins in Chemokines, Suggesting
a Mechanism for Coreceptor Selectivity
formed an R5 virus into an X4 virus. A double mutation,
S313R and D329Q or D333N, caused the same pheno-
type conversion [4]. (Residues are numbered throughout
according to the BH10 isolate sequence [5]). Thus, small
changes in the V3 sequence are sufficient to switch
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New York, New York 10010 neutralizing determinant (PND) of HIV-1 [6]. HIV-neu-
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Spectroscopy the binding of gp120 to either the CCR5 or CXCR4 che-
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The structure of the gp120 core of both an X4 labora-D-07745 Jena
Germany tory-adapted virus and that of an R5 primary isolate in
complex with a CD4 fragment and the Fab of a gp120-
specific antibody have been solved [7, 8]. However,
crystals could be obtained only for gp120 lacking theSummary
first three variable loops, including V3, and the struc-
tures of V4 and V5 have not been defined. Despite theThe V3 loop of the HIV-1 envelope glycoprotein gp120
dramatic antigenic differences between the laboratory-is involved in binding to the CCR5 and CXCR4 corecep-
adapted X4 and the primary R5 isolates, the structurestors. The structure of an HIV-1MN V3 peptide bound to
of their gp120 cores are very similar [7]. These data,the Fv of the broadly neutralizing human monoclonal
together with chimeric substitution and sequence analysis,antibody 447-52D was solved by NMR and found to
indicate that coreceptor choice and neutralization resis-be a  hairpin. This structure of V3MN was found to
tance involve the major variable loops, V1/V2 and V3.have conformation and sequence similarities to hair-
As an alternative to studying the V3 conformation inpins in CD8 and CCR5 ligands MIP-1, MIP-1, and
the intact gp120 molecule, complexes of V3 peptidesRANTES and differed from the  hairpin of a V3IIIB pep-
with antibodies elicited against gp120 or HIV-1 can betide bound to the strain-specific murine anti-gp120IIIB
used. Wilson and coworkers determined the crystal struc-antibody 0.5. In contrast to the structure of the bound
tures of V3MN peptides bound to three murine mono-V3MN peptide, the V3IIIB peptide resembles a  hairpin
clonal antibodies generated against a cyclic 40-residuein SDF-1, a CXCR4 ligand. These data suggest that
V3 peptide comprising the entire V3 loop [9–11]. Anthe 447-52D-bound V3MN and the 0.5-bound V3IIIB
extended conformation and multiple turn conformationsstructures represent alternative V3 conformations re-
were observed, respectively, for the N- and C-terminalsponsible for selective interactions with CCR5 and
segments of the V3 loop flanking the central GPGR se-CXCR4, respectively.
quence. The GPGR segment itself was found to adopt
dual conformations. However, the short epitopes recog-
Introduction nized by these anti-peptide antibodies did not permit
the determination of the global conformation of the V3MNThe binding of the human immunodeficiency virus loop. A strain-specific HIV-1-neutralizing murine mono-
type-1 (HIV-1) to its target cells is mediated primarily by clonal antibody, 0.5, raised against gp120IIIB, recog-the envelope glycoprotein (gp120) of the virus. Binding nizes a significantly longer epitope in a V3IIIB peptide.of gp120 to CD4, a molecule found on the surface of The peptide bound to this antibody formed a  hairpin
both T cells and macrophages, triggers conformational not observed in the X-ray studies [12]. The HIV-1IIIB strainchanges in gp120 that expose a binding site to either contains a QR insertion near the tip of the V3 loop pres-
CCR5 or CXCR4 chemokine receptors. Only after bind- ent in less than 10% of HIV-1 isolates. This insertion is
ing to the chemokine receptors can the virus penetrate not found in the MN strain, which is a representative of
into the target cell. The third hypervariable region of the subtype B viruses common in Europe and North
gp120 (V3 loop, residues 303–340) is directly involved America [13].
in the binding to the chemokine receptors [1, 2]. The V3 The human monoclonal antibody 447-52D is one of
sequence determines whether the virus binds to CCR5 the most broadly neutralizing and most potent anti-V3
(designated R5 virus) and, therefore, infects macro- antibodies that have been studied to date. It binds to
phages or whether it binds to CXCR4 (designated the intact virions from clades A, B, D, F, G, and H [14] and
X4 virus) and infects T cells ([3] and the references neutralizes primary isolates from several clades, includ-
therein). A single mutation in the V3 loop, D329R, trans-
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ing X4 and R5 viruses [15–20]. Antibody 447-52D binds trum (Figure 1A) and by measurement of an HOHAHA
spectrum of a 15N-labeled peptide in complex with unla-to different V3 peptides with association constants of
2  105 –108 M1, the highest of which is only one order beled Fv, which eliminated all interference by the Fv
resonances (data not shown). Short 15N T2 relaxationof magnitude lower than its affinity to the corresponding
gp120 protein [21]. Since 447-52D was elicited during times were measured for MNR311–MNK328, indicating that
some backbone immobilization of four additional resi-the course of HIV-1 infection and neutralizes a broad
spectrum of HIV-1 isolates, it most likely recognizes a dues, MNR311, MNT326, MNT327, and MNK328 (Figure 1B),
occurs because of their proximity to the epitope andnative V3 conformation. Consequently, the structure of
447-52D complexed with V3 peptides can serve as a minor interactions with the 447 Fv (see below).
reliable model for understanding the interactions be-
tween gp120 and anti-HIV antibodies directed against
Solution Structure of the Antibody-Bound V3MN PeptideV3 and for identifying features on the surface of the V3
The structure of the bound V3MN epitope was determinedloop that interact with the chemokine receptors on the
with 305 NMR-derived distance (90 long- and medium-target cells.
range), 10 dihedral angle, and 2 hydrogen bond con-Here, we present the structure of a V3MN peptide (308YN-
straints. The superposition of the 29 lowest-energyKRKRIHI—GPGRAFYTTKNIIG332, where “—” represents
structures that satisfy the experimental restraints withthe position of a two-residue insertion in V3IIIB) as recog-
no NOE violations larger than 0.5 A˚ and no torsion anglenized by the Fv fragment of the HIV-1-neutralizing hu-
violations exceeding 5 is shown in Figure 2A. The overallman monoclonal antibody 447-52D (447 Fv). The back-
structure of the epitope (312–327gp120) is well defined, withbone of the bound peptide forms a  hairpin with two
root-mean-square deviation (rmsd) values of 0.37 A˚ andantiparallel  strands linked by an inverse  turn. The
1.17 A˚ for the backbone and heavy atoms, respectively.N-terminal  strand and four residues from the C-ter-
The structural statistics and rmsd values are presentedminal  strand contribute almost all the interactions be-
in Table 1. The Ramachandran plot (data not shown) oftween the V3 loop and the 447 Fv, indicating the expo-
the mean structure of the complex suggests that the sure of these residues and, thereby, their potential to
and  angles of the structure predominantly occupybe involved in chemokine receptor binding. The V3 
allowed regions, except for MNG319 and MNG321.hairpin shows conformation and sequence similarity to
As shown in Figures 2A–2C, the epitope forms a a  hairpin in CD8 and to  hairpins in MIP-1, MIP-1,
hairpin consisting of two antiparallel  strands formedand RANTES, which are implicated in binding to CCR5.
by residues MNR313–MNI316 and MNA323–MNT326 linked byThe  hairpin conformation of a V3IIIB peptide bound to
a reverse turn. NOE interactions characteristic of a 0.5-Fv is different and is shown to resemble a  hairpin
hairpin conformation were observed between backbonein SDF-1, a CXCR4 ligand. This data suggests that these
atoms of the N-terminal and C-terminal halves. Thesetwo  hairpin conformations of the V3 loop are responsi-
interactions include MNR313 HN/MNT326 HN, MNR313 HN/ble for coreceptor selectivity.
MNT327 H, MNI314 H/MNY325 H, and MNH315 HN/MNY325
H. The expected MNK312 H/MNT327 H and MNI314 H/
MNT326 HN NOE interactions could not be assigned be-Results
cause of resonance overlap. 3 JHNH coupling constants
higher than 8.4 Hz, typical of a  strand, were measuredMapping the V3MN Epitope
NMR dynamic filtering was used to map the epitope for MNI314, MNH315, MNI316, MNY325, MNT326, and MNT327.
In the NMR structure of the V3 epitope (312–327gp120),within the V3MN peptide recognized by the 447 Fv. Pep-
tide protons that do not interact with the Fv retain con- the  hairpin is stabilized by a network of hydrogen
bonds between the two  strands (Figure 2C). Two pairssiderable mobility in comparison with peptide protons
that interact with the Fv. As a result of the long mixing of hydrogen bonds are formed between MNR313 and
MNT326 and between MNH315 and MNF324. The side chainsperiod used in the HOHAHA and ROESY spectra, the cros-
speaks of peptide protons interacting with the Fv as well of residues MNR313, MNH315, MNF324, and MNT326 form
the lower face of the  hairpin, while the side chains ofas of most Fv protons vanish, while the crosspeaks of
residues in the flexible parts of the peptide that do not MNI314, MNI316, MNA323, and MNY325 form the upper face
(Figure 2C). The structure of the  hairpin is stabilizedinteract with the Fv are still observed. These include
seven residues of the C-terminal region (MNT326–MNG332) by extensive hydrophobic interactions involving MNI314,
MNI316, and MNY325. The side chain of MNK312 forms addi-and two of the N-terminal segment (MNN309 and MNR311).
The proton chemical shifts of these residues were practi- tional stabilizing interactions with MNT327, MNI314, and
MNY325. On the lower face of the  sheet, only interac-cally identical to those observed for the free peptide,
confirming that they do not interact or have only very tions between MNF324 and MNT326 could be observed,
indicating that the lower face is less compact than theminor interactions with the antibody. The HOHAHA cros-
speaks of MNK312–MNR322 were undetectable in the upper face. The precision and accuracy of the conforma-
tion of the side chains are expected to be improvedspectra, implying strong interactions with 447 Fv. The
crosspeaks of MNA323, MNF324, and MNY325 were weak, when the structure of the entire Fv complex with the
V3 peptide is solved. However, because of side chainindicating that these three residues are within the V3MN
epitope. By this method, the epitope recognized by the interactions within the peptide, the conformation of
some of the side chains is very well defined in the struc-447 Fv was mapped to gp120 residues MNK312–MNY325.
This definition of the epitope was confirmed by examina- ture of the bound V3MN peptide. For example, the heavy-
atom rmsd values for MNI314 and MNI316 are 0.175 andtion of the peak intensity in a TROSY 1H-15N HSQC spec-
V3 Structure and HIV Coreceptor Selectivity
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Figure 1. NMR Mapping of the 447-52D
Epitope
(A) A diagram showing the variations in the
1HN/15N crosspeak intensities of a 15N TROSY-
HSQC spectrum recorded with uniformly
15N-labeled V3MN peptide bound to unlabeled
447 Fv.
(B) A diagram showing the variations of the
15N T2 relaxation times of the bound V3MN pep-
tide along the peptide sequence. The asterisk
denotes an overlap between residues MNK310
and MNK328.
0.361 A˚, respectively, for the best backbone superposi- N-terminal segment. The dominance of the N-terminal
segment and MNR322 in the interactions with the 447 Fvtion of residues MNK312–MNT327.
(68% of the interactions with the 447 Fv) is supported
by the dynamic-filtering experiments, which showedThe GPG Segment Bound to 447 Fv Forms
an Inverse  Turn that the segment MNK312–MNR322 was strongly immobi-
lized upon binding to the 447 Fv. MNT326 and MNT327The GPG sequence linking the  strands forms an in-
verse  turn stabilized by an i,i	 2 hydrogen bond be- have one interaction each with the Fv. The T2 relaxation
times of MNT326 and MNT327 are comparable to those oftween the carbonyl oxygen of MNG319 and the amide
proton of MNG321. This  turn conformation is corrobo- peptide residues that interact more extensively with the
Fv, most likely because of interactions between the tworated by the sequential H
-H and H
-HN connectivities
between MNP320 and MNG319 (typical of proline in a trans-  strands in the  hairpin involving these two residues
(see above).conformation), an NOE between MNP320 H and MNR322
HN, and a strong sequential interaction between MNG321 About half (55 out of 120) of the observed peptide
side chain interactions with the Fv are with aromaticHN and MNP320 H. The  and  angles of MNP320 are72
and 65, in excellent agreement with the characteristic rings, indicating that the antibody binding site is rich in
aromatic residues, as can be deduced from the se-inverse  turn angles [22]. These differ markedly from
the  and  angles for a type II  turn (60 and 120) quence of the variable loops [23]. The existence of this
aromatic environment is also reflected in the unusualand a type I  turn (60 and 30). The side chain of
MNR322 interacts extensively with the MNP320 and MNG319 high-field chemical shift observed for the protons of
MNG319, MNP320, and MNR322 caused by the local ringresidues that form the inverse  turn, thus defining the
orientation of the arginine side chain with respect to the current fields induced by aromatic amino acid residues
[24]. As the antibody resonances have not yet beenturn (rmsd of 0.74 A˚ for the best backbone superposition
of MNK312–MNT327). assigned, the peptide-Fv interactions could not be as-
signed to the specific 447 Fv residues involved.
The amide protons of MNI314 and MNI316 were foundThe V3MN Residues Interacting with the Antibody
Extensive interactions between the peptide and the 447 to exchange slowly with the solvent and were detected
even 24 hr after exchanging H2O with D2O. All otherFv were observed in the 13C-edited NOESY spectrum.
As shown in Figure 3, the N-terminal segment MNK312– amide protons disappeared because of fast exchange.
This slow exchange of MNI314 and MNI316 amide protonsMNI316 contributes 59% of the peptide interactions with
the Fv, with MNI316 contributing the largest number of indicated that they are protected from exchange with
the solvent because of hydrogen bonds formed in theinteractions. The C-terminal segment comprising resi-
dues MNR322–MNT327 contributes 33% of the interactions complex. As these two residues are not involved in hy-
drogen bonding within the  hairpin, they must be in-of the peptide with the Fv, significantly less than the
Structure
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Table 1. NMR Constraints and Structural Statistics for the
Refined 447 Fv-Bound V3MN Peptide (29 Structures)
NMR distance constraints
Total 305
Intraresidue 155
Sequential 60
Medium- and long-range 90
Dihedral angle 10
NOE violations
Maximum individual violation (A˚) 0.5
Rmsd of NOE violation 0.0012  0.0026
Deviation from ideal covalent geometry
Bond lengths (A˚) 0.0015  0.0002
Bond angles () 0.4109  0.0105
Improper angles 0.1394  0.0183
Mean rmsd values (A˚)
All backbone atoms 0.37
All heavy atoms 1.17
using the SPASM program [25]. We found that, out of
9848  hairpins that differed from the V3MN  hairpin by
a backbone rmsd of less than 2.5 A˚, 512 contained the
motif IxI or homologs thereof, with conservative replace-
ment of isoleucine by leucine or valine. Out of the six V3
residues found in this study to interact most extensively
with the 447 Fv, MNI314, MNI316, and MNR322 are the most
conserved, with 94%, 82%, and 91% conservation, re-
spectively [26]. Of the 512  hairpins, 54 and 60 had
arginine or lysine separated by two or three residues,
respectively, from the IxI motif or its homologs (conser-
vative replacement of the isoleucine). In V3MN, the two
isoleucine residues are separated by histidine, which
interacts extensively with the antibody but is conserved
in only 46% of HIV-1 isolates [26]. In a search in which
the “x” in the IxI motif was restricted to an aromatic
residue, but not tryptophan, 10  hairpins were found
to have the (I/L/V) (H/F/Y) (I/L/V) x x x (R/K) motif. Three
of these were human proteins; two were CD8 [27, 28]
(in free and complexed form), and the third was an Alz-
heimer precursor protein [29]. As shown in Figure 4A
the orientations of the two isoleucine residues and the
positively charged side chain (K56 in CD8 and MNR322
in V3) are very similar in V3MN and CD8. The alignment
of CD8 and V3MN sequences is presented in Figure 4D.
The search revealed that only seven of the homolo-
Figure 2. The Solution Structure of the V3MN Epitope (312–327gp120MN) gous  hairpins had the sequence (I/L/V) (H/F/Y) (I/L/V)
Bound to the 447 Fv x x (R/K). The four that were of human origin included
(A) Backbone superposition of 29 lowest-energy structures. MIP-1 [30], RANTES [31], Met-RANTES [32], and an
(B) A ribbon diagram of the energy-minimized average structure; oncogene product involved in T cell prolymphocytic leu-
the terminal residues of the  strands are numbered.
kemia [33]. The sequence alignments of the MIP-1 and(C) A stereo representation of V3MN bound to the 447 Fv showing
RANTES chemokines with the V3MN peptide are shownside chain interactions and hydrogen bonds within the peptide (red).
Side chains pointing out from the page, yellow; side chains pointing in Figure 4D. Of the three nonhuman  hairpins, one was
inward, green. a synthetic anti-HIV protein [34] and the other was a
viral macrophage inflammatory protein-II (v-MIP) [35].
Five out of the seven peptides bind to CCR5. Although,volved in intermolecular bonds to the Fv. The slow ex-
change of the amide protons indicates a very tight according to the homology search, the basic amino acid
in RANTES and MIP-1 is separated by two residuesbinding of the V3MN peptide to the 447 Fv.
from the (I/L/V) (H/F/Y) (I/L/V) motif and by three residues
in V3MN, the side chain of the basic residue points in theThe Structure of V3MN Bound to the 447 Fv Is Highly
Homologous to  Hairpins in CD8, MIP-1, same direction in the three proteins, and the overall
topology of the (I/L/V) (H/F/Y) (I/L/V) sequence is similar,MIP-1, and RANTES
In an attempt to reveal potential structural homologs for as shown in Figure 4B (H is neutral and aromatic at pH
above the imidazole pKa). To test the uniqueness ofthe V3  hairpin, we searched the Protein Data Bank
V3 Structure and HIV Coreceptor Selectivity
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Figure 3. Intermolecular Interactions of the
V3MN Peptide with the 447 Fv
The total number of intermolecular interac-
tions observed in the NOESY spectra is
shown for each residue of the epitope.
the similarity between V3MN and the corresponding  KSIRIQR and RAFVTI of V3IIIB are superimposed over
the segments IVARLKN and NRQVCI of SDF-1 (see Fig-hairpins in MIP-1 and RANTES, we repeated the search
for homologous  hairpins with a sequence (I/L/V) (H/F/ ure 4D). Interestingly, residues IIIBG319 and IIIBP320 at the
tip of the turn protrude beyond the common structure asY) (I/L/V) x x x x (R/K). Only human MIP-1 and RANTES
and two rat proteins were revealed by the search, show- a result of the longer loop. SDF-1 has an arginine residue
after the reverse turn, as does V3IIIB, but this arginine ising that the results are almost the same whether or not
the positively charged residue is separated from the shifted one residue downstream in the SDF-1 sequence.
triad motif by two or four residues.
As shown in Figure 4D in MIP-1, the residue following Discussion
the aromatic residue is glutamine, instead of a nonpolar
aliphatic amino acid; however, the remaining three resi- The Neutralizing Face of the V3 Loop
In this study, the structure of a 23-residue HIV-1MN V3dues of the motifs mentioned above are conserved [(I/L/
V) (H/F/Y) x x x (R/K) and (I/L/V) (H/F/Y) x x x x x (R/K)]. peptide bound to the Fv fragment of the human mono-
clonal antibody 447-52D in solution was solved by multi-The side chains of MIP-1V41, F42, Q43, and R46 super-
impose on the side chains of the corresponding residues dimensional heteronuclear NMR, and the interactions
between the peptide and 447 Fv were assigned to spe-MNI314, MNH315, MNI316, and MNR322 in V3MN. The back-
bone rmsd between MIP-1 and the structure of V3MN cific peptide residues. The V3 epitope (312–327gp120) bound
to 447 Fv forms a  hairpin consisting of two antiparallelbound to 447-52D is 1.88 A˚ for the segment IHIGP-
GRAFY, revealing the same structural homology be-  strands comprising residues MNR313–MNI316 and
MNA323–MNT326 linked by an inverse GPG  turn (Figuretween V3MN and MIP-1 as that observed between V3MN
and MIP-1 and RANTES. 2C). Residues MNK312, MNR313, MNI314, MNH315, and
MNI316 from the N-terminal strand and residues MNR322,
MNA323, MNF324, and MNY325 from the C-terminal strandThe V3IIIB Structure Recognized by 0.5 Fv
Is Homologous to a  Hairpin in SDF-1 form most of the intermolecular interactions of the V3MN
peptide with the 447 Fv (Figure 3). These residues formThe IIIB strain has an atypical two-residue insertion at
positions IIIBQ317 and IIIBR318 of the V3 loop. This inser- an exposed surface of the V3 loop that has the potential
to interact with the chemokine receptors CCR5 andtion does not affect the length of the  strands in V3IIIB
bound to 0.5 Fv in comparison with V3MN bound to 447- CXCR4. Indeed, alanine scanning showed that V3 resi-
dues MNK312, MNI314, MNR322, and MNF324 are important52D Fv but, rather, creates a six-residue loop comprising
residues IIIBQ317, IIIBR318, IIIBG319, IIIBP320, IIIBG321, and for CCR5 binding [38]. Moreover, each of these residues
is highly conserved: MNI314 is found in 94% of HIV-1IIIBR322, instead of the three-residue GPG loop in V3MN
[12]. The reverse turn in V3IIIB is shifted one residue up- isolates, MNK312 and MNR322 are identical or conserva-
tively replaced by arginine or lysine, respectively, in 95%stream and comprises the segment RGPG to maintain
the central location of the reverse turn at the tip of the and 91.5% of HIV-1 isolates, and MNF324 is conserved
in 71% of HIV-1 isolates [26]. hairpin. Therefore, to accommodate the two-residue
insertion, the coordinates for IIIBG319 and IIIBP320 at the Previously we showed that, in the complex of a V3IIIB
peptide bound to the strain-specific HIV-1-neutralizingtip of the turn were excluded when the SPASM program
was used to search the Protein Data Bank for structural murine monoclonal antibody 0.5, residues IIIBI314, IIIBR315,
IIIBQ317, IIIBP320, IIIBR322, and IIIBF324 form most of thehomologs of the V3IIIB  hairpin. We found that, out of
5734  hairpins that differed from the V3IIIB  hairpin by interactions with the antibody [39]. Thus, the NMR stud-
ies to date indicate that the N-terminal segment closea backbone rmsd of less than 1.0 A˚, only the structure
of SDF-1 [36, 37] in the Protein Data Bank contained to the tip of the V3 loop and, to a lesser extent, the
C-terminal segment following the GPG sequence arethe (I/L/V/A) (H/R/K) (I/L/V/A) motif (H is included, since
it is positively charged at pH below the imidazole pKa). recognized by HIV-1-neutralizing anti-V3 antibodies.
The crystal structure of V3MN peptides in complex withThe backbone superposition of the SDF-1  hairpin over
the V3IIIB  hairpin (Figure 4C) shows an excellent fit, three murine monoclonal antibodies, 50.1, 59.1, and
58.2, elicited against a cyclic peptide comprising thewith a backbone rmsd of 0.47 A˚ when the segments
Structure
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antibody 447-52D, excluding MNT326 and MNT327. While
antibodies 59.1 and 58.2 showed no obvious preference
for antibody interactions with the N-terminal strand of
the epitope, antibody 50.1 interacts only with the N-ter-
minal strand and the beginning of the turn.
The  Hairpin Is a Common Structural Feature
of V3 Loops of Different HIV-1 Strains
Since antibody 447-52D was elicited against the HIV-1
virus, binds to intact virions [14], and neutralizes a broad
spectrum of viruses [18], it recognizes a V3 conformation
that exists on virus particles. Flexible V3 peptides, when
bound to such an antibody, will assume the conforma-
tion against which this antibody was elicited. The anti-
body 0.5, which we studied previously, was elicited
against soluble gp120, and, therefore, this antibody also
recognizes a V3 conformation in the context of the whole
protein [12]. In contrast, the linear V3MN peptide and its
cyclic form used as an immunogen in obtaining the three
anti-peptide antibodies studied by crystallography are
mostly flexible in the free form and, except for a  turn
in the GPGR segment, they do not show any detectable
secondary structure in aqueous solution [40].
We previously observed a  hairpin conformation with
a type VI  turn in the V3IIIB peptide bound to 0.5 Fv
[12]. Therefore, both our present and previous findings
suggest that the  hairpin is conserved in the V3 region
of gp120 from different virus strains. This conclusion is
consistent with the prediction that the V3 loop of most
HIV-1 strains forms a  strand,  turn, and  strand
conformation [26, 41]. It is important to note that, while
the X-ray structures agree with the secondary structure
predictions with respect to the N-terminal segment, they
either provide no information or have different structures
(multiple turns) for the C-terminal residues [9–11].
The Flexibility of the GPGR Sequence
The GPGR segment was found to adopt different types
of reverse turn when bound to different HIV-1 antibodies,
as summarized in Figures 5A and 5B. The inverse  turn
observed in V3MN bound to the 447 Fv differs from the
type II and type I  turns in the V3MN peptide bound to
Figure 4. Structural Homology of the V3  Hairpins with CD8, the anti-peptide antibodies and from the type VI cis-
MIP-1, MIP-1, RANTES, and SDF-1 proline  turn that was observed in the RGPG segment
Backbone superposition of the 447 Fv-bound V3MN peptide (blue) at the center of a V3IIIB peptide bound to the 0.5 Fv
with (A) CD8 (red) and (B) CCR5 natural ligands MIP-1 (green), [12]. The different types of turn suggest a conformational
MIP-1 (magenta), and RANTES (yellow). The side chains of I314, flexibility in the GPGR sequence, a flexibility that is likelyI316, and R322 in V3MN and their equivalents in CD8 (L50, L52, and
conferred by the two glycine residues flanking the pro-K56), MIP-1 (I40, L42, R45, or R47), MIP-1 (V41, Q43, R46, or K48)
line. As a result of this flexibility, the GPGR segmentand RANTES (V40, V42, K45, or R47) are shown.
(C) Backbone superposition of the 0.5 Fv-bound V3IIIB peptide may adopt different conformations according to the se-
(cyan) with SDF-1 (purple). Side chains of I314 and I316 of V3IIIB and quence of the V3. Thus, it is possible that the rare QR
A40 and L42 in SDF-1 are shown. insertion that precedes the GPGR segment in V3IIIB
(D) Sequence alignment of the V3 peptides with the homologous  caused the shift in the  turn in order to preserve thehairpins in CD8, MIP-1, MIP-1, RANTES, and SDF-1.
alignment of the hydrogen bonds in the  hairpin [12].
This may conserve the spatial arrangement of the side
chains crucial for binding to the chemokine receptors.entire V3 loop was solved by X-ray crystallography [9–
11]. Antibody 50.1 interacts with MNK312–MNP320, anti- In addition, conformational flexibility of the V3 loop may
contribute to the topology of the  hairpin surface ex-body 59.1 interacts with MNI316–MNF324, and antibody
58.2 interacts with MNR313–MNY325. The combined epi- posed to the HIV coreceptors and allow the V3 region
to optimize its conformation to maximize its binding totope recognized by the three anti-peptide antibodies
overlaps the epitope recognized by human monoclonal one or more of the chemokine receptors (see below).
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Figure 5. The Structure of the V3MN Peptide
Bound to the 447 Fv Compared with the
Structures of V3 Peptides Bound to Anti-Pep-
tide Antibodies
(A) Backbone superposition of the bound
V3MN peptides in complex with the 447 Fv
(blue) or with antibodies 50.1 (yellow), 59.1
(green), and 58.2 (red).
(B) The epitope recognized by each antibody
and the type of turn the bound peptide forms
in each complex. Residues in  strands are
underlined. The residues in bold letters form
turns.
Alternative Conformations of the V3 Loop the exposure of residue R41 and the burial of residues
A40 and L42 (Figure 6C). It is evident that the topologyAlthough both the V3IIIB peptide bound to 0.5 Fv and
the V3MN peptide bound to 447 Fv form  hairpins, they of the side chains of these amino acid triads is inverted
in these two chemokines.differ in the network of hydrogen bonds within the two
peptides that stabilize the  hairpin conformation. While, The topology of the V3 loop with respect to native
gp120 is unknown. Figures 6D and 6E show the orienta-in the V3IIIB peptide, IIIBK312, IIIBI314, and IIIBI316 form hydro-
gen bonds with IIIBI327, IIIBV325, and IIIBA323, respectively, tion of V3MN and V3IIIB obtained by superpositioning them
over the homologous  hairpins in MIP-1 and SDF-1,there is a one-residue shift in the intrapeptide hydrogen
bonds in the V3MN peptide, where residues MNR313 and respectively. This superpositioning shows a remarkable
resemblance in the orientation of the triad residues be-MNH315 form hydrogen bonds with residues MNT326 and
MNF324, respectively. As a result of this shift, side chains tween V3MN (IHI) and MIP-1 (IFL) and between V3IIIB
(IRI) and SDF-1 (ARL). As with MIP-1 and SDF-1, thepointing upward in V3IIIB point downward in V3MN, as if
the two conformations were related by an imaginary orientation of the side chains of the V3MN triad IHI is
inverted in comparison with the orientation of the sideinversion axis. As shown in Figure 6A, superpositioning
of the IHI segment of V3MN over the corresponding IRI chains of the V3IIIB IRI triad (Figures 6D and 6E). Thus,
the alternative conformations found in the V3MN and V3IIIBsegment in V3IIIB results in a 180 difference in the direc-
tion of the continuation of the  turn and the second   hairpins are highly analogous to the alternative  hair-
pin conformations found in MIP-1/MIP-1/RANTESstrand. In the context of the gp120 protein, residues
exposed in one type of  hairpin may be buried in the and SDF-1, respectively.
Varying conformations of the V3 loop around theother  hairpin conformation and vice versa. These dif-
ferences in orientation may have profound implications GPGR  turn were previously observed by Wilson and
coworkers when comparing three different anti-V3 pep-on coreceptor and antibody binding.
Superpositioning of the IFL segment in MIP-1, the tide antibodies in complex with a V3MN peptide. However,
the  hairpin conformation was not observed [11], thusVFV segment in RANTES, and the VFQ segment in MIP-
1 over the ARL motif of SDF-1 created the same 180 preventing the observation of the one-residue shift in
the hydrogen bond network and its implications on siderotation as that observed between V3MN and V3IIIB (Figure
6A). The effect of this change in conformation is illus- chain orientation and surface topology.
trated in a comparison of MIP-1 and SDF-1 (Figures
6B and 6C). The ribbon diagrams (in red) show that the The Homology between the V3 Loop and  Hairpin
Structures of MIP-1/MIP-1/RANTES and SDF-1overall spatial orientation of the backbones of these
chemokines is quite similar. Nevertheless, the space- The correlation between the conformation of V3MN bound
to the 447 Fv and the  hairpins in MIP-1, MIP-1, andfilling blowup of the  hairpins clearly shows that, in
MIP-1, residue F41 is buried and residues I40 and L42 RANTES suggests that the conformation of V3 recog-
nized by the 447 Fv may be the conformation interactingare exposed (Figure 6B). In SDF-1, a 180 flip results in
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Figure 6. Analogy between the Dual  Hairpin Conformations Formed by V3 Loops and the Conformations of the Homologous  Hairpins in
MIP-1 and SDF-1
(A) Backbone superposition of the homologous  hairpins in SDF-1 (yellow), V3IIIB (green), MIP-1 (red), and V3MN (blue) obtained by best
superposition of triads I40-F41-L42 (MIP-1), A40-R41-L42 (SDF-1), I314-H315-I316 (V3MN), and I314-R315-I316 (V3IIIB). A ribbon diagram of (B)
MIP-1 and (C) SDF-1. The  hairpins homologous to V3 are shown in a space-filling view, while nearby residues are shown in sticks. (D)
V3MN and (E) V3IIIB presented in a space-filling representation. The residues of the above triads are highlighted. Residues I40 and L42 in MIP-
1, A40 and L42 in SDF-1, and I314 and I316 in both V3MN and V3IIIB are light green. The aromatic residues F41 in MIP-1 and H315 in V3MN
are dark green, and R41 in SDF-1 and R45 in MIP-1 are blue.
with CCR5. Thus, the VFV motif in RANTES is part of sponding region in MIP-1 is only 7%, it is unlikely that
a monoclonal antibody such as 447-52D will crossreactthe 2 strand (residues 38–43), which forms a  sheet
with the 1 strand of the protein. Both  strands are with MIP-1, MIP-1, and RANTES. The correlation be-
tween the structure of V3IIIB bound to 0.5 and that ofimplicated in binding to CCR5 [42]. The corresponding
region of the V3 loop also participates in chemokine SDF-1 (Figure 6) also suggests that the conformation of
bound V3IIIB represents that of the V3 loop in X4 HIV-1binding [38]. The observation that affinity-purified anti-
V3 antibodies isolated from HIV-1-infected patients viruses.
Further evidence supporting the proposed homologycrossreact with MIP-1 and RANTES [43] further sup-
ports the apparent homology between the structures of between V3 and the  hairpin structures of the chemo-
kines, which are ligands for the HIV-1 coreceptors, isV3 and these chemokines. However, since the sequence
identity between the 447-52D epitope and the corre- provided by experiments from several groups that have
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shown that V3 loop-derived peptides can inhibit viral recognized by an HIV-1-neutralizing antibody, the anti-
body can induce the peptide to adopt the conformationentry into target cells in a coreceptor-specific manner
[44–46]. against which the antibody was elicited. In such a case,
it would not matter whether the peptide used to obtain
the complex is from an X4 or an R5 virus. This would
The Mechanism for Coreceptor Selectivity explain why the V3MN peptide, which represents the V3
Four residues implicated in CCR5 binding (K312, I314, sequence of an X4 virus, binds to the 447 Fv in an R5
R322, and F324) are contained in the V3  hairpin [38] topology. Clearly, the proof for the involvement of such
recognized by 447-52D. The orientation of each of these conformational changes in coreceptor selectivity will re-
amino acids is reversed in the  hairpin conformations quire determination of the structure of gp120, including
of bound V3MN and V3IIIB, and it is difficult to envision V3 in complex with the chemokine receptors CXCR4
how these alternative conformations could bind to the and CCR5. Nevertheless, our NMR structural studies of
same receptor. If V3MN bound to 447 Fv is in an R5 virus V3 loop peptides bound to HIV-1-neutralizing antibodies
conformation and the V3IIIB bound to 0.5 is in an X4 virus and structural comparisons with the natural ligands of
conformation, the differences in these critical residues the HIV-1 coreceptors provide compelling data that illu-
could account for coreceptor selectivity. minate the mechanisms underlying coreceptor selectiv-
As noted above, the overall spatial arrangements of ity and bypass the difficulties in crystallizing membrane
the backbones of MIP-1/MIP-1/RANTES and SDF-1 proteins, which preclude such experiments at this time.
show significant homology (Figures 6B and 6C), and However, it is not altogether clear how antibody 447-
common sequence motifs appear in both. Further analo- 52D can neutralize both X4 and R5 viruses. One possible
gies emerge upon inspection of their electrostatic prop- explanation is that there is equilibrium between the two
erties. As seen in Figure 6C, the 1 strand adjacent  hairpin conformations of the V3 and that both are
to the ARL motif of SDF-1 contains positively charged present under physiological conditions. The selection
residues K24, K27, and H25, which can be positively of the coreceptor is dictated mostly by residue 329 and,
charged, depending on its pKa. In contrast, MIP-1 has to a lesser extent, by the charges of residues 312 and
I24, A25, and Y27 in the corresponding positions of the 313. Since residue 329 is outside the epitope recognized
1 strand (Figure 6B), creating a neutral and more- by 447-52D, the antibody can neutralize X4 and R5 vi-
hydrophobic surface adjacent to the I40-F41-L42 triad ruses, which have very similar sequences in the 447-
in the three-dimensional structure of the protein. It is 52D epitope (312–327gp120). V3 conformational flexibility
known that an increased positive charge at the base of could shift the equilibrium to the R5 conformation upon
the V3 loop transforms an R5 virus into an X4 virus. binding of the virus to 447-52D. Interestingly, an equilib-
Residue 329 is very important for coreceptor selectivity. rium between two  hairpin conformations differing in
It is two residues downstream of the  hairpin C termi- the pattern of hydrogen bonds was observed by NMR
nus, and mutation from D to R results in a switch from in the C chemokine lymphotactin [48], providing clear
an R5 to an X4 isolate [4]. It is possible that placing a evidence for the feasibility of the V3 flexibility model.
positively charged residue at this position in V3 results This dual conformation of the lymphotactin  hairpin
in a change in the charge of the surface that mimics the was accompanied by a shift of one residue in the pattern
positively charged 1 strand in SDF-1 (see above). If of hydrogen bonds with a third  strand that forms a
this is correct, it suggests that an increased positive three-strand sheet with the hairpin. Similar interactions
charge and a  hairpin conformation that mimics the between V3 and other regions of gp120 could play a
SDF-1 surface are involved in CXCR4 binding, while role in the conformational equilibrium of V3.
a less positive surface and an MIP-1-like  hairpin
conformation mimic the MIP-1, MIP-1, and RANTES
Biological Implications
surface involved in CCR5 binding.
Our structural studies on anti-gp120 and anti-HIV-1 anti-
As stated earlier, the 447-52D antibody was elicited
bodies directed against V3 show that the V3 loop can
in an HIV-1-infected individual, and, therefore, the exact
assume two types of  hairpin, differing in the network
strain and V3 sequence responsible for its production
of hydrogen bonds by a one-residue shift. As a result,
are unknown. Antibody 447-52D neutralizes a broad
the orientation of the V3 residues within gp120 and their
spectrum of HIV-1 isolates from different clades, includ-
exposure are very different for the two V3 conforma-
ing primary X4 and R5 viruses. The epitope recognized
tions, even though the sequence at the central ten-resi-
by 447-52D does not include residue 329, which is the
due segment of V3 is highly homologous. One type of
most crucial for coreceptor selectivity. Moreover, the
 hairpin shows structural and sequence similarity to
consensus sequence of clade B R5 viruses in the region
MIP-1, MIP-1, and RANTES  hairpin structures impli-
of the 447-52D epitope (312–327gp120) differs by only one
cated in CCR5 binding, and the other V3hairpin confor-
residue from the MN sequence (R313 is replaced by Ser
mation shows structural and sequence similarity to a 
in R5 viruses). Apparently this replacement does not
hairpin in SDF-1, a CXCR4 ligand. The data suggest a
interfere with 447-52D binding, since V3IIIB contains this role for the dual V3 conformations in coreceptor selec-
replacement and HIV-1IIIB is neutralized by 447-52D [47]. tivity.
The importance of residue 313 for coreceptor selectivity,
but its minor effect, if any, on 447-52D binding, could
Experimental Proceduresbe due to the fact that this residue is at the periphery
of the 447-52D epitope. Sample Preparation
Since V3 peptides are flexible and the V3 loop of X4 The V3MN peptide 308–332gp120MN (YNKRKRIHIGPGRAFYTTKNIIG)
linked to a fusion protein was expressed in Escherchia coli, cleaved,and R5 viruses may differ only slightly in the epitope
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and purified as previously described [49] (note that the sequential basis of characteristic backbone NOEs between two anti-parallel
 strands. Secondary structure elements and rmsd values werenumbering system in V3MN is interrupted because of a rare two-
residue insertion in HIV-1IIIB, and, therefore, residues 317 and 318 calculated with the MOLMOL program 2.6 [60]. Structures were
further analyzed with Aqua/Procheck-NMR [61] and displayed withare not present in V3MN). The 447 Fv was expressed in the BL21(DE3)-
pLysS strain [50]. The Fv-peptide complex (28.7 kDa) was prepared InsightII (MSI).
by the addition of a 20% molar excess of the peptide to a dilute Fv
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